Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Aim low.
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, 1 Gustave L. Levy Place, New York, NY 10029, USA. ira.nash@msnyuhealth.org
Ira S
IS
Nash
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000517:prevention & control*; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors